CStats is the trading name of Chris Brown a Sydney statistician who studied and has worked for the University of Sydney. Chris graduated with a Bachelor of Science in maths and stats at the University of Sydney in 2002 and in 2011 completed the Masters of Biostatistics administered through the Biostatistics Collaboration of Australia.  After graduation, Chris worked at software company SPSS until 2005. Chris then became a Biostatistician and Research Fellow at the NHMRC Clinical Trials Centre (CTC) at the University of Sydney. The CTC provides assistance to investigators designing and conducting clinical trials in Australia. He recently spend 3 years at the National Cancer Registry Ireland working on a pharmacoepidemiology project in ovarian cancer.

Chris  become an academic in 2009 and quickly developed a publication track record. He is an author on over 20 peer-reviewed manuscripts and been a co-author on a number of conference presentations and posters at national conferences and large international meetings. A member of the Statistical Society of Australia, his main statistical research interests are in areas of sequential trial design, randomisation methods, time to event and interim analysis. He also has an interest in applications of statistical methods to genetic research in particular Genome Wide Association Studies. He has a wide range of teaching experience in the areas of biostatistics. At the post-graduate level he was a course coordinator of the Controlled Trials subject in the School of Public Health Masters program and a subject in the Masters of Clinical Trials Research program. He has been also been involved in teaching a number of other courses, lectures and concept development workshops. He is the current consultant statistician at the Central Clinical School at Nepean hospital.

Pharmacoepidemiology

Chris recently spent 3 years in Cork working on an epidemiological project at the National Cancer Registry Ireland. The project evaluated three groups of commonly taken drugs (NSAIDs, statins and beta-blockers) for potential associations between extent of Ovarian cancer at diagnosis, risk of recurrence and survival.  There is more details about the project here.

Support available

Do you have a data problem? Chris may be able to help – for more information see the consulting page.